>

Sigalia Heifetz - CLAL BIOTECHNOLOGY Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>CLA</div>
  Director
We currently do not have informatin regarding Sigalia Heifetz. This executive tanure with CLAL BIOTECHNOLOGY is not currenlty determined.
Age: 53  Director Since 2012      
972 3 612 1616  http://www.cbi.co.il

Management Efficiency

The company has return on total asset (ROA) of (5.15) % which means that it has lost $5.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.79) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. CLAL BIOTECHNOLOGY has Current Ratio of 3.6 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Oded ShoseyovEVOGENE LTD
2018
Itai CohenSOLEGREEN LTD
2017
Erez BalashaSOLEGREEN LTD
2018
Ronit CohenSOLEGREEN LTD
2013
Jonathan HahnKAMADA
2010
Leon RecanatiEVOGENE LTD
2005
Nir PelegSOLEGREEN LTD
2017
Kinneret SavitzkyEVOGENE LTD
2010
Shlomo FedidaSOLEGREEN LTD
2018
Avi BzuraKADIMASTEM
2013
Adina MakoverEVOGENE LTD
2003
Arie WeberKITOV PHARMA LTD
2017
Abraham MeizlerKADIMASTEM
2014
Gwen MelincoffKAMADA
2017
Eli ZangvilEVOGENE LTD
2006
Joseph EldorKADIMASTEM
2018
Moran SherfBlauKITOV PHARMA LTD
2013
Hillel RozanskiSOLEGREEN LTD
2018
Julien RuggieriKADIMASTEM
2010
Aharon SchwartzPROTALIX BIOTHERAP
2014
Ido AgmonKITOV PHARMA LTD
2016

Company Summary

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.CLAL BIOTECHNOLOGY (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 14 people.

CLAL BIOTECHNOLOGY Leadership Team

Ofer Goldberg, VPView
Sigalia Heifetz, DirectorView
Shmuel Rubinstein, External DirectorView
Tomer Babai, DirectorView
Dafna Gruber, DirectorView
Aharon Schwartz, DirectorView
Gavriel Barabash, DirectorView
Isaac Kohlberg, DirectorView
Nofar Malovani, DirectorView
Assaf Segal, CFOView
Ofer Gonen, Vice PresidentView
Avraham Fischer, Chairman of the BoardView
Yuval Yanai, External DirectorView
Julian Adams, President Chief Scientific OfficerView
Orit Lidor, VP and General CounselView

Stock Performance Indicators

Did you try this?

Run Sync Your Broker Now

   

Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

CLAL BIOTECHNOLOGY Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Pepco Holdings and Alibaba Group Holding. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check out Trending Equities. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page